United Therapeutics Corporation (UTHR) Q3 2025 Earnings Call Transcript
Total Revenues $800 million, representing 7% growth from the third quarter of 2024. This growth was driven by continued year-over-year growth in total Tyvaso and Orenitram sales, reflecting patient demand and the resilience of the commercial strategy and execution.
Tyvaso Revenue Growth Continued double-digit revenue growth for total Tyvaso. This growth is attributed to no material impact from the launch of YUTREPIA, increased disease awareness due to competition, and the convenience and dosing potential of the Tyvaso DPI platform.
Tyvaso DPI Dosing Behavior Patients averaged 9 breaths per treatment using nebulized Tyvaso delivery, which increased to a 12-breath equivalent or 64 micrograms with Tyvaso DPI. The launch of 80-microgram cartridges and higher dose combination kits (96 and 112 micrograms) is expected to provide added convenience and unlock new revenue potential.
Remodulin Launch of the new RemunityPRO pump during the third quarter. The pump is small, discrete, and features user-friendly remote instructions, automated priming, and easy filling. Its lower flow rates may enable more patients to initiate therapy at home instead of requiring a hospital stay.
Trade with 70% Backtested Accuracy
Analyst Views on UTHR
About UTHR
About the author
United Therapeutics Reports Positive Phase 1 Results for MiroliverELAP
- Clinical Trial Success: In a Phase 1 study for acute liver failure, five patients treated with miroliverELAP for at least 44 hours met the survival endpoint, demonstrating the product's potential to provide critical liver support in dire situations.
- Safety Assessment Positive: No unexpected serious adverse events were reported during a subsequent 32-day follow-up, indicating the safety of miroliverELAP in clinical applications and laying the groundwork for future commercialization.
- Future Research Plans: Full study results are expected to be published in the second half of 2026, further validating the efficacy and safety of miroliverELAP, which could drive its market adoption.
- Stable Stock Performance: United Therapeutics' stock has increased approximately 26.89% over the past 12 months, currently trading at $471, reflecting relatively strong market performance despite facing some technical pressure in the short term.
United Therapeutics Upgraded to Overweight with Price Target of $535.73
- Rating Upgrade: United Therapeutics (UTHR) has received an upgrade to an overweight rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target Set: Analysts have set a price target of $535.73, indicating confidence in the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance market confidence in United Therapeutics, potentially increasing the liquidity and attractiveness of its stock.
- Investor Strategy: By raising the rating and price target, analysts may aim to guide investors to reassess the investment value of United Therapeutics, thereby enhancing its competitiveness in the biopharmaceutical sector.
WYNN Options Volume Surges 148.3% with 19,101 Contracts Traded
- Surge in Options Volume: Wynn Resorts (WYNN) has seen an options trading volume of 19,101 contracts today, equivalent to approximately 1.9 million shares, which represents a significant 148.3% of its average daily trading volume over the past month, indicating heightened market interest in the stock.
- High-Frequency Trading Insight: Among all contracts, the $110 strike call option expiring on March 20, 2026, stands out with 15,632 contracts traded, representing about 1.6 million shares, suggesting that investors are increasingly optimistic about future price increases.
- Market Dynamics Observation: In comparison, Vanda Pharmaceuticals (VNDA) also exhibited strong options trading today with 22,662 contracts, equivalent to approximately 2.3 million shares, reflecting 147.5% of its average daily trading volume over the past month, highlighting market interest in the biotech sector.
- Investor Sentiment Analysis: VNDA's $8 strike call option has also gained traction with a trading volume of 4,435 contracts, representing about 443,500 shares, indicating a bullish sentiment among investors regarding the company's future performance, which could drive its stock price higher.
S&P 500 Futures Steady in Pre-Market Session; United Therapeutics and Intel Underperform
Stock Market Opening: U.S. stock markets are set to open in two hours.
UiPath Inc. Performance: UiPath Inc. (PATH) saw an increase of 8.1% in pre-market trading.
CCC Intelligent Solutions Holdings Inc. Performance: CCC Intelligent Solutions Holdings Inc. (CCC) experienced a rise of 4.4% in pre-market trading.
IJK Shares Near 52-Week High of $99.90, Last Trade at $99.22
- Stock Performance: IJK's share price has a 52-week low of $71.69 and a high of $99.90, with the last trade at $99.22, indicating that the stock is nearing its historical peak, reflecting growing market confidence in the company.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with a useful technical analysis perspective, aiding in trend assessment and optimizing investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell “units” that can be created or destroyed based on demand, impacting the supply and demand of underlying assets.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), enabling timely market insights and investment opportunities.
Significant Options Trading on Wednesday: UTHR, URGN, DSGN
UroGen Pharma Options Activity: UroGen Pharma Ltd (URGN) has seen a significant options volume of 20,539 contracts today, equating to about 2.1 million underlying shares, which is 192% of its average daily trading volume over the past month.
High Volume Call Option for URGN: The $24 strike call option expiring on February 20, 2026, has particularly high activity with 10,010 contracts traded, representing approximately 1.0 million underlying shares.
Design Therapeutics Options Activity: Design Therapeutics Inc (DSGN) has recorded an options volume of 5,000 contracts today, representing around 500,000 underlying shares, which is 164.8% of its average daily trading volume over the past month.
High Volume Call Option for DSGN: The $9 strike call option expiring on January 16, 2026, has seen all 5,000 contracts traded today, corresponding to approximately 500,000 underlying shares.
United Therapeutics Reports Positive Phase 1 Results for MiroliverELAP
- Clinical Trial Success: In a Phase 1 study for acute liver failure, five patients treated with miroliverELAP for at least 44 hours met the survival endpoint, demonstrating the product's potential to provide critical liver support in dire situations.
- Safety Assessment Positive: No unexpected serious adverse events were reported during a subsequent 32-day follow-up, indicating the safety of miroliverELAP in clinical applications and laying the groundwork for future commercialization.
- Future Research Plans: Full study results are expected to be published in the second half of 2026, further validating the efficacy and safety of miroliverELAP, which could drive its market adoption.
- Stable Stock Performance: United Therapeutics' stock has increased approximately 26.89% over the past 12 months, currently trading at $471, reflecting relatively strong market performance despite facing some technical pressure in the short term.
United Therapeutics Upgraded to Overweight with Price Target of $535.73
- Rating Upgrade: United Therapeutics (UTHR) has received an upgrade to an overweight rating, reflecting analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target Set: Analysts have set a price target of $535.73, indicating confidence in the company's growth potential, which could drive the stock price towards this target.
- Market Reaction: The upgrade in rating and price target may enhance market confidence in United Therapeutics, potentially increasing the liquidity and attractiveness of its stock.
- Investor Strategy: By raising the rating and price target, analysts may aim to guide investors to reassess the investment value of United Therapeutics, thereby enhancing its competitiveness in the biopharmaceutical sector.
WYNN Options Volume Surges 148.3% with 19,101 Contracts Traded
- Surge in Options Volume: Wynn Resorts (WYNN) has seen an options trading volume of 19,101 contracts today, equivalent to approximately 1.9 million shares, which represents a significant 148.3% of its average daily trading volume over the past month, indicating heightened market interest in the stock.
- High-Frequency Trading Insight: Among all contracts, the $110 strike call option expiring on March 20, 2026, stands out with 15,632 contracts traded, representing about 1.6 million shares, suggesting that investors are increasingly optimistic about future price increases.
- Market Dynamics Observation: In comparison, Vanda Pharmaceuticals (VNDA) also exhibited strong options trading today with 22,662 contracts, equivalent to approximately 2.3 million shares, reflecting 147.5% of its average daily trading volume over the past month, highlighting market interest in the biotech sector.
- Investor Sentiment Analysis: VNDA's $8 strike call option has also gained traction with a trading volume of 4,435 contracts, representing about 443,500 shares, indicating a bullish sentiment among investors regarding the company's future performance, which could drive its stock price higher.
S&P 500 Futures Steady in Pre-Market Session; United Therapeutics and Intel Underperform
Stock Market Opening: U.S. stock markets are set to open in two hours.
UiPath Inc. Performance: UiPath Inc. (PATH) saw an increase of 8.1% in pre-market trading.
CCC Intelligent Solutions Holdings Inc. Performance: CCC Intelligent Solutions Holdings Inc. (CCC) experienced a rise of 4.4% in pre-market trading.
IJK Shares Near 52-Week High of $99.90, Last Trade at $99.22
- Stock Performance: IJK's share price has a 52-week low of $71.69 and a high of $99.90, with the last trade at $99.22, indicating that the stock is nearing its historical peak, reflecting growing market confidence in the company.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides investors with a useful technical analysis perspective, aiding in trend assessment and optimizing investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell “units” that can be created or destroyed based on demand, impacting the supply and demand of underlying assets.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), enabling timely market insights and investment opportunities.
Significant Options Trading on Wednesday: UTHR, URGN, DSGN
UroGen Pharma Options Activity: UroGen Pharma Ltd (URGN) has seen a significant options volume of 20,539 contracts today, equating to about 2.1 million underlying shares, which is 192% of its average daily trading volume over the past month.
High Volume Call Option for URGN: The $24 strike call option expiring on February 20, 2026, has particularly high activity with 10,010 contracts traded, representing approximately 1.0 million underlying shares.
Design Therapeutics Options Activity: Design Therapeutics Inc (DSGN) has recorded an options volume of 5,000 contracts today, representing around 500,000 underlying shares, which is 164.8% of its average daily trading volume over the past month.
High Volume Call Option for DSGN: The $9 strike call option expiring on January 16, 2026, has seen all 5,000 contracts traded today, corresponding to approximately 500,000 underlying shares.
